Imfinzi

Imfinzi

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Durvalumab
Indications/Uses
Locally advanced, unresectable non-small cell lung cancer (NSCLC) in patients whose disease has not progressed following platinum-based chemoradiation therapy. 1st-line treatment of patients w/ extensive-stage small cell lung cancer (ES-SCLC) in combination w/ etoposide & either carboplatin or cisplatin.
Dosage/Direction for Use
IV Locally advanced NSCLC 10 mg/kg infusion over 1 hr every 2 wk, until disease progression or unacceptable toxicity. ES-SCLC 1,500 mg as infusion in combination w/ chemotherapy every 3 wk (21 days) for 4 cycles followed by 1,500 mg every 4 wk as monotherapy until disease progression or unacceptable toxicity. Patients weighing ≤30 kg Wt based-dosing equiv to 20 mg/kg in combination w/ chemotherapy every 3 wk (21 days) for 4 cycles, followed by 20 mg/kg every 4 wk as monotherapy until wt increases to >30 kg.
Contraindications
Special Precautions
Monitor for signs & symptoms of pneumonitis, colitis or diarrhea, adrenal insufficiency, type 1 DM, hypophysitis or hypopituitarism, rash or dermatitis & other potential immune-mediated adverse reactions; patients for abnormal liver, renal & thyroid function tests prior to, & periodically during treatment. May affect ability to drive & operate machinery. Not recommended during pregnancy & in women of childbearing potential not using effective contraception during treatment, & for at least 3 mth after the last dose. Do not breastfeed during treatment & for at least 3 mth after the last dose. Childn <18 yr.
Adverse Reactions
Cough/productive cough; abdominal pain, diarrhea; hypothyroidism; rash, pruritus; pyrexia; upper resp tract infections. Pneumonitis, dysphonia; increased ALT & AST; hyperthyroidism; increased blood creatinine, dysuria; night sweats; peripheral oedema; pneumonia, oral candidiasis, dental & oral soft tissue infections, influenza; myalgia; infusion-related reaction.
ATC Classification
L01XC28 - durvalumab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Imfinzi conc for soln for infusion 50 mg/mL
Packing/Price
10 mL x 1's;2.4 mL x 1's
/singapore/image/info/imfinzi conc for soln for infusion 50 mg-ml/120 mg-2-4 ml?id=7dbd7ef5-5cbf-4eef-846f-aab800eace85
/singapore/image/info/imfinzi conc for soln for infusion 50 mg-ml/500 mg-10 ml?id=c9949c9d-5426-4dbc-8e50-aab800eace85
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in